4597Solasia Pharma K.K.4597 info
$0.34info9.09%24h
Global rank24499
Market cap$56.63M
Change 7d-14.29%
YTD Performance4.35%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    Solasia Pharma K.K. (4597) Stock Overview

    Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.

    4597 Stock Information

    Symbol
    4597
    Address
    Sumitomo Fudosan Shiba-Koen TowerTokyo, 105-0011Japan
    Founded
    -
    Trading hours
    -
    Website
    https://www.solasia.co.jp
    Country
    🇯🇵 Japan
    Phone Number
    81 3 5843 8045

    Solasia Pharma K.K. (4597) Price Chart

    -
    Value:-

    Solasia Pharma K.K. Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.33647611370088676
    N/A
    Market Cap
    $56.63M
    N/A
    Shares Outstanding
    168.31M
    N/A
    Employees
    27.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org